Literature DB >> 25794093

Dynamic contrast-enhanced MRI for the detection of prostate cancer: meta-analysis.

Cher Heng Tan1, Brian Paul Hobbs, Wei Wei, Vikas Kundra.   

Abstract

OBJECTIVE: The purpose of this study was to systematically review and meta-analyze dynamic contrast-enhanced MRI (DCE-MRI) for the detection of prostate cancer in comparison with standard evaluation with T2-weighted imaging.
MATERIALS AND METHODS: A PubMed electronic database search for the terms "dynamic contrast-enhanced," "prostate," and "MRI" was completed for articles up to September 17, 2013. All included studies had histopathologic correlation. Two by two contingency data were constructed for each study. A binormal bayesian ROC model was used to estimate and compare sensitivity, specificity, and AUC among eligible modalities.
RESULTS: Both DCE-MRI (0.82-0.86) and diffusion-weighted MRI (DWI) (0.84-0.88) yielded significantly better AUC than T2-weighted imaging (0.68-0.77). Moreover, partial AUC for the combination of DCE-MRI, DWI, and T2-weighted imaging was improved significantly (0.111; 0.103-0.119) when compared with DCE-MRI alone (0.079; 0.072-0.085) and T2-weighted imaging alone (0.079; 0.074-0.084) but not DWI alone (0.099; 0.091-0.108). Sensitivity and specificity were similar among the four modalities.
CONCLUSION: DCE-MRI improves AUC of tumor detection overall compared with T2-weighted imaging alone. Methods for DCE-MRI analysis require standardization, but visual analysis performs similar to semiquantitative methods. A two-parameter approach using DCE-MRI and T2-weighted imaging or DWI and T2-weighted imaging may be sufficient, and the latter may be more favorable for most routine prostate cancer imaging.

Entities:  

Keywords:  MRI; cancer; dynamic contrast-enhanced MRI (DCE-MRI); prostate

Mesh:

Substances:

Year:  2015        PMID: 25794093      PMCID: PMC5152763          DOI: 10.2214/AJR.14.13373

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  47 in total

Review 1.  Local staging of prostate cancer with MRI.

Authors:  Fatma Nur Soylu; Scott Eggener; Aytekin Oto
Journal:  Diagn Interv Radiol       Date:  2012-03-08       Impact factor: 2.630

2.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.

Authors:  David Moher; Alessandro Liberati; Jennifer Tetzlaff; Douglas G Altman
Journal:  J Clin Epidemiol       Date:  2009-07-23       Impact factor: 6.437

3.  Dynamic TurboFLASH subtraction technique for contrast-enhanced MR imaging of the prostate: correlation with histopathologic results.

Authors:  G J Jager; E T Ruijter; C A van de Kaa; J J de la Rosette; G O Oosterhof; J R Thornbury; S H Ruijs; J O Barentsz
Journal:  Radiology       Date:  1997-06       Impact factor: 11.105

Review 4.  Advancements in MR imaging of the prostate: from diagnosis to interventions.

Authors:  David Bonekamp; Michael A Jacobs; Riham El-Khouli; Dan Stoianovici; Katarzyna J Macura
Journal:  Radiographics       Date:  2011 May-Jun       Impact factor: 5.333

5.  Usefulness of prebiopsy multifunctional and morphologic MRI combined with free-to-total prostate-specific antigen ratio in the detection of prostate cancer.

Authors:  Joan C Vilanova; Carles Barceló-Vidal; Josep Comet; Maria Boada; Joaquim Barceló; Joana Ferrer; Joan Albanell
Journal:  AJR Am J Roentgenol       Date:  2011-06       Impact factor: 3.959

Review 6.  Imaging of organ-confined prostate cancer: functional ultrasound, MRI and PET/computed tomography.

Authors:  Philippe Puech; Damien Huglo; Grégory Petyt; Laurent Lemaitre; Arnauld Villers
Journal:  Curr Opin Urol       Date:  2009-03       Impact factor: 2.309

7.  MRI in the detection of prostate cancer: combined apparent diffusion coefficient, metabolite ratio, and vascular parameters.

Authors:  Sophie F Riches; Geoffrey S Payne; Veronica A Morgan; Samir Sandhu; Cyril Fisher; Michael Germuska; David J Collins; Alan Thompson; Nandita M deSouza
Journal:  AJR Am J Roentgenol       Date:  2009-12       Impact factor: 3.959

8.  Prognostic value of microvessel density in prostate cancer: a tissue microarray study.

Authors:  Andreas Erbersdobler; Hendrik Isbarn; Kira Dix; Isabel Steiner; Thorsten Schlomm; Martina Mirlacher; Guido Sauter; Alexander Haese
Journal:  World J Urol       Date:  2009-08-28       Impact factor: 4.226

9.  Prostate cancer: relationships between postbiopsy hemorrhage and tumor detectability at MR diagnosis.

Authors:  Tsutomu Tamada; Teruki Sone; Yoshimasa Jo; Akira Yamamoto; Takenori Yamashita; Naoto Egashira; Shigeki Imai; Masao Fukunaga
Journal:  Radiology       Date:  2008-06-06       Impact factor: 11.105

Review 10.  Angiogenesis imaging in the management of prostate cancer.

Authors:  Anwar R Padhani; Christopher J Harvey; David O Cosgrove
Journal:  Nat Clin Pract Urol       Date:  2005-12
View more
  30 in total

Review 1.  Anatomic and Molecular Imaging in Prostate Cancer.

Authors:  Eric T Miller; Amirali Salmasi; Robert E Reiter
Journal:  Cold Spring Harb Perspect Med       Date:  2018-03-01       Impact factor: 6.915

2.  Comparison of multiparametric and biparametric MRI of the prostate: are gadolinium-based contrast agents needed for routine examinations?

Authors:  Daniel Junker; Fabian Steinkohl; Veronika Fritz; Jasmin Bektic; Theodoros Tokas; Friedrich Aigner; Thomas R W Herrmann; Michael Rieger; Udo Nagele
Journal:  World J Urol       Date:  2018-08-04       Impact factor: 4.226

3.  Biopsy targeting with dynamic contrast-enhanced versus standard neuronavigation MRI in glioma: a prospective double-blinded evaluation of selection benefits.

Authors:  Vera C Keil; Bogdan Pintea; Gerrit H Gielen; Susanne Greschus; Rolf Fimmers; Jürgen Gieseke; Matthias Simon; Hans H Schild; Dariusch R Hadizadeh
Journal:  J Neurooncol       Date:  2017-04-19       Impact factor: 4.130

4.  Variability in Quantitative DCE-MRI: Sources and Solutions.

Authors:  Harrison Kim
Journal:  J Nat Sci       Date:  2018

5.  Dynamic contrast-enhanced MRI of the prostate: An intraindividual assessment of the effect of temporal resolution on qualitative detection and quantitative analysis of histopathologically proven prostate cancer.

Authors:  Justin M Ream; Ankur M Doshi; Diane Dunst; Nainesh Parikh; Max X Kong; James S Babb; Samir S Taneja; Andrew B Rosenkrantz
Journal:  J Magn Reson Imaging       Date:  2016-09-20       Impact factor: 4.813

Review 6.  Implementation of Multi-parametric Prostate MRI in Clinical Practice.

Authors:  Andrea S Kierans; Samir S Taneja; Andrew B Rosenkrantz
Journal:  Curr Urol Rep       Date:  2015-08       Impact factor: 3.092

Review 7.  Prostate imaging reporting and data system version 2 (PI-RADS v2): a pictorial review.

Authors:  Elmira Hassanzadeh; Daniel I Glazer; Ruth M Dunne; Fiona M Fennessy; Mukesh G Harisinghani; Clare M Tempany
Journal:  Abdom Radiol (NY)       Date:  2017-01

8.  MRI versus ⁶⁸Ga-PSMA PET/CT for gross tumour volume delineation in radiation treatment planning of primary prostate cancer.

Authors:  Constantinos Zamboglou; Gesche Wieser; Steffen Hennies; Irene Rempel; Simon Kirste; Martin Soschynski; Hans Christian Rischke; Tobias Fechter; Cordula A Jilg; Mathias Langer; Philipp T Meyer; Michael Bock; Anca-Ligia Grosu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-11-23       Impact factor: 9.236

Review 9.  The expanding landscape of diffusion-weighted MRI in prostate cancer.

Authors:  Andreas G Wibmer; Evis Sala; Hedvig Hricak; Hebert Alberto Vargas
Journal:  Abdom Radiol (NY)       Date:  2016-05

Review 10.  Prostate cancer risk stratification with magnetic resonance imaging.

Authors:  Ely R Felker; Daniel J Margolis; Nima Nassiri; Leonard S Marks
Journal:  Urol Oncol       Date:  2016-03-31       Impact factor: 3.498

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.